Rashi Peripherals Limited has filed a NIL statement of deviation for its IPO proceeds utilization during Q3FY26 under Regulation 32 of SEBI Listing Regulations. The company confirmed to BSE and NSE on February 3, 2026, that there were no deviations or variations in the utilization of proceeds from its Rs. 600.00 crore Initial Public Offer during the quarter ended December 31, 2025.

Regulatory Compliance and Filing Details

The company submitted the NIL deviation statement to both stock exchanges, with BSE scrip code 544119 and NSE symbol RPTech. The filing was made pursuant to Regulation 32 requirements and was reviewed by the company's Audit Committee in its meeting held on February 3, 2026. Company Secretary and Compliance Officer Arvind Bajoria signed the compliance document, while Chief Financial Officer Himanshu Kumar Shah authenticated the deviation statement.

IPO Proceeds Utilization Status

The monitoring report reveals comprehensive utilization across the three main IPO objects. The company has successfully completed debt repayment and working capital funding, with only General Corporate Purpose showing remaining funds of Rs. 1.61 crore out of the original Rs. 8.14 crore allocation.

Timeline Extension for General Corporate Purpose

The company has extended the utilization timeline for General Corporate Purpose funds through a Board resolution dated April 21, 2025. Originally scheduled for completion by the end of fiscal year 2024, the timeline has been extended to the end of fiscal year 2026 or thereafter. This extension provides flexibility to deploy the remaining Rs. 1.61 crore based on business requirements without requiring shareholder approval as no deviations occurred.

Audit Committee and Monitoring Agency Review

CARE Ratings Limited, serving as the monitoring agency, confirmed that all fund utilization remains consistent with the original offer document disclosures. The Audit Committee reviewed the utilization status and found no material deviations from the disclosed objects. Both the Audit Committee and auditors provided no adverse comments on the IPO proceeds utilization during the quarter.

Rashi Peripherals Limited announced significant board changes on February 3, 2026, with the appointment of two additional directors following recommendations from the Nomination and Remuneration Committee. The appointments were made in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Key Board Appointments

The board approved two strategic appointments that will strengthen the company's leadership structure:

Rajesh Goenka's Leadership Profile

Mr. Rajesh Goenka brings substantial experience to his new role as Chief Executive Officer. He holds a Bachelor's degree in Chemical Engineering from Pune University and has accumulated over 25 years of extensive experience in sales and marketing. His association with the company dates back to 2008, where he has played a pivotal role in driving growth through strategic vision and leadership.

Goenka has been instrumental in shaping the company's remarkable journey, leading it to achieve consistent double-digit compound annual growth rate (CAGR) for over 20 years. His appointment as Whole-Time Director and CEO reflects the board's confidence in his ability to continue steering the company's growth trajectory.

Dr. Indumati Gopinathan's Expertise

Dr. Indumati Gopinathan joins as an Additional Non-Executive Independent Director, bringing diverse professional experience from the healthcare sector. She is an experienced pathologist with MBBS and MD degrees from Seth G.S. Medical College, Mumbai, and has led pathology departments in leading hospitals with specialization in ocular pathology and uropathology.

Her professional portfolio includes:

• Current role as Independent Director at Thyrocare Technologies Limited
• Leadership positions in National AIDS Control Organization and Indian Medical Association
• Pioneer in telemedicine initiatives
• Completion of Masterclass on Women Directorship by NSE Limited
• Active involvement in healthcare governance and social impact projects

Regulatory Compliance and Next Steps

Both appointments comply with SEBI regulations and require approval from the company's members. The directors have confirmed that neither appointee is debarred from holding directorial positions by SEBI or any other regulatory authority. The appointments reflect Rashi Peripherals' commitment to strengthening its board composition with experienced professionals who can contribute to the company's strategic objectives and governance standards.